Impact of Finer Segmentation of Reimbursement Functional Categories and Changes in Reimbursement Prices
First written in FY2016. 11 of 17 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Other".
- FY2026JACC coverage under Japan's health insurance system for the osteoarthritis of the knee indicationAnnual report
「Manufacturing and marketing approval was obtained in May 2025, and insurance coverage began in January 2026.」
Regarding the expansion of JACC's indication to osteoarthritis of the knee, insurance listing was achieved in January 2026 after approval was obtained. - FY2025-H1Increase in JACC's insurance reimbursement price contributed to higher salesAnnual report
「In addition, the increase in the insurance reimbursement price from June under the FY2024 revision of medical fees contributed to the increase in sales.」
The filing states that the increase in JACC's insurance reimbursement price from June 2024 contributed to higher sales. - FY2024Revision of JACC's insurance reimbursement priceAnnual report
「June 2024: Revision of the insurance reimbursement price for JACC, an autologous cultured cartilage product.」
The section on insurance function classifications and reimbursement prices states that JACC's insurance reimbursement price was revised in June 2024. - FY2023-Q2RestatedAnnual report
「For JACE, a limit is set on the number of sheets eligible for reimbursement for each patient's treatment series: 40 sheets for burn treatment, or 50 sheets only where medically necessary; 30 sheets for treatment of congenital giant pigmented nevus; and 50 sheets for treatment of epidermolysis bullosa, including dystrophic and junctional types.」
The reimbursement limits for JACE by indication continue to be disclosed. - FY2023-Q1RestatedAnnual report
「For JACE, a limit is set on the number of sheets eligible for reimbursement for each patient's treatment series: 40 sheets for burn treatment, or 50 sheets only where medically necessary; 30 sheets for treatment of congenital giant pigmented nevus; and 50 sheets for treatment of epidermolysis bullosa, including dystrophic and junctional types.」
The reimbursement limits for JACE by indication continue to be disclosed. - FY2022-Q1RestatedAnnual report
「For JACE, a limit is set on the number of sheets eligible for reimbursement for each patient's treatment series: 40 sheets for burn treatment, or 50 sheets only where medically necessary; 30 sheets for treatment of congenital giant pigmented nevus; and 50 sheets for treatment of congenital epidermolysis bullosa, including dystrophic and junctional types.」
The reimbursement limits for JACE by indication continue to be disclosed. - FY2020RestatedAnnual report
「For JACE, a limit is set on the number of sheets eligible for reimbursement per patient per treatment series: 40 sheets for burn treatment, or 50 sheets only where medically necessary; 30 sheets for treatment of congenital giant pigmented nevus; and 50 sheets for treatment of congenital epidermolysis bullosa, including dystrophic and junctional types.」
The reimbursement limits for JACE by indication continue to be disclosed, with further relaxation pursued based on actual usage. - FY2020-Q3RestatedAnnual report
「Regarding insurance coverage for JACE, the points to note concerning reimbursement were revised in April 2018. For burn treatment, the reimbursement limit was increased from 40 sheets per patient per treatment series to a maximum of 50 sheets, but only where medically necessary.」
The reimbursement limit for JACE continues to be described as increasing from 40 sheets to 50 sheets where medically necessary. - FY2020-Q2RestatedAnnual report
「As part of its regenerative medicine products business, the company proceeded with the manufacture and sale of JACE, an autologous cultured epidermis product, and JACC, an autologous cultured cartilage product.」
This filing does not provide further details on changes to the insurance reimbursement limits, but there have been no material changes to the existing insurance system environment, including the conditional increase in JACE's reimbursement limit from 40 sheets to 50 sheets. - FY2019-Q3RestatedAnnual report
「Since April 2018, the rules governing reimbursement have been revised, raising the reimbursement limit for burn treatment from 40 sheets per patient per course of treatment to 50 sheets where medically necessary.」
The disclosure continues to explain that the reimbursement limit for JACE was raised from 40 to 50 sheets where medically necessary. - FY2019-Q2RestatedAnnual report
「Since April 2018, the rules governing reimbursement have been revised, raising the reimbursement limit from 40 sheets per patient per course of treatment to 50 sheets where medically necessary.」
The disclosure continues to explain that the reimbursement limit for JACE was raised from 40 to 50 sheets where medically necessary. - FY2018MitigatedAnnual report
「Since April 2018, the rules governing specified medical materials have been revised, raising the limit from 40 sheets per patient per course of treatment to 50 sheets where medically necessary.」
For JACE treatment of severe burns, the reimbursement limit on the number of sheets used was raised from 40 to 50, subject to conditions. - FY2018-Q3RestatedAnnual report
「Since April 2016, the subdivision of the reimbursement categories has made it possible to receive reimbursement for ① harvesting and culture kits even when manufacturing is discontinued.」
The disclosure continues to explain the system under which reimbursement for harvesting and culture kits is available even when manufacturing is discontinued as a result of the subdivision of the reimbursement categories. - FY2018-Q2RestatedAnnual report
「Since April 2016, the subdivision of the reimbursement categories has made it possible to receive reimbursement for ① harvesting and culture kits even when manufacturing is discontinued.」
The disclosure continues to explain the system under which reimbursement for harvesting and culture kits is available even when manufacturing is discontinued as a result of the subdivision of the reimbursement categories. - FY2017-Q2RestatedAnnual report
「As a result, a certain level of reimbursement became available even when manufacturing was discontinued before transplantation for reasons such as the patient's death during manufacturing, creating a more favorable environment for developing the regenerative medicine products business.」
The disclosure continues to explain the effects of the subdivision of the reimbursement categories and the availability of a certain level of reimbursement from April 2016, with no substantive change from the previous quarter. - FY2017-Q1MitigatedAnnual report
「As a result, a certain level of reimbursement became available even when manufacturing was discontinued before transplantation for reasons such as the patient's death during manufacturing, creating a more favorable environment for developing the regenerative medicine products business.」
The division of the reimbursement categories into 2 categories and the revision of reimbursement prices created a system under which a certain level of reimbursement is available even when manufacturing is discontinued before transplantation, reducing part of the previously disclosed risk of being unable to recognize sales. - FY2016First statedAnnual report
「From April 2016, the reimbursement category was subdivided into ① harvesting and culture kits and ② preparation and transplantation kits. This reduced the risk that sales could not be recognized for reasons such as a patient's death, but this subdivision of the functional categories had no precedent, and its impact was unknown.」
The disclosure states that the reimbursement categories for JACE and JACC were divided into 2 kits and reimbursement prices were revised, while the impact on orders and sales remained unknown.